News & Updates
Filter by Specialty:
Show Multimedia Only

ALEX final OS analysis: Alectinib superior to crizotinib in 1L ALK+ NSCLC
26 Oct 2025
byNatalia Reoutova
Final overall survival (OS) data analysis from the phase III ALEX study presented at ESMO 2025 indicates alectinib is superior to crizotinib in patients with previously untreated ALK-positive (ALK+) non-small-cell lung cancer (NSCLC).
ALEX final OS analysis: Alectinib superior to crizotinib in 1L ALK+ NSCLC
26 Oct 2025
What is the most cost-effective CRC screening strategy in Asians?
26 Oct 2025
byNatalia Reoutova
Faecal immunochemical test (FIT) positive result followed by artificial intelligence (AI)–assisted colonoscopy represents the most cost-effective colorectal cancer (CRC) screening strategy in an Asian population, according to a study from the Chinese University of Hong Kong (CUHK).







